Patent · US Active

Use of HLA-B*1301 allele

US9567636B2 · kind B2 · utility

0Cited by

0References

3Claims

0Family size

Assignee

Shandong Provincial Institute of Dermatology and V · CN

Inventors

Furen Zhang · Jinan, CN
Shumin Chen · Beijing, CN
Hong Liu · Pennington, US

Key dates

Filing date	Jun 18, 2013
Grant date	Feb 14, 2017
Priority date	—
Expiry date	Jun 18, 2033

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12Q2600/172
WIPO fieldBiotechnology
WIPO sectorChemistry

Abstract

The present invention discloses uses of a HLA-B*1301 allele, comprising: 1) a use of a substance for detecting whether a person has the HLA-B*1301 allele in preparation of a product for evaluating a risk of adverse drug reactions in response to dapsone in the person; 2) a method for detecting or evaluating a risk of adverse drug reaction in response to dapsone in a person, comprising detecting whether the person has the HLA-B*1301 allele, wherein, a person with LA-B*1301 allele suffers a higher risk of adverse drug reaction upon being administered dapsone, as compared with a person without HLA-B*1301 allele, and a person with LA-B*1301 alleles at both chromosomes of a pair of homologous chromosomes suffers a higher risk of adverse drug reaction upon being administered dapsone, as compared with a person with HLA-B*1301 allele at only one of a pair of homologous chromosomes.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.